BMS and Five Prime push the immune-oncology deal bandwagon along

Brisk business in the immuno-oncology deal space continues with Bristol-Myers Squibb linking with Five Prime Therapeutics in a discovery, development, and commercialization alliance worth up to $350m for therapies targeted at two undisclosed immune checkpoint pathways.